High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
Researchers sought to determine if vagal nerve activity could predict overall survival and progression-free survival in patients with R/R DLBCL and MM, respectively.
Researchers sought to determine whether conversion of MRD status during maintenance would affect risk of disease progression in patients with MM.
Ide-cel significantly improves progression-free survival and response compared with standard regimens.